BioSig Technologies Files 8-K with Key Agreements and Sales
Ticker: STEX · Form: 8-K · Filed: May 30, 2024 · CIK: 1530766
| Field | Detail |
|---|---|
| Company | Biosig Technologies, Inc. (STEX) |
| Form Type | 8-K |
| Filed Date | May 30, 2024 |
| Risk Level | medium |
| Pages | 7 |
| Reading Time | 8 min |
| Key Dollar Amounts | $0.001, $1.91, $1.78, $3.0 million, $2.3875 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, financials
Related Tickers: BSGM
TL;DR
BioSig dropped an 8-K: material agreements, equity sales, and financials are in. Check it.
AI Summary
On May 29, 2024, BioSig Technologies, Inc. filed an 8-K report detailing several key events. The company entered into a material definitive agreement, reported unregistered sales of equity securities, and disclosed other events. The filing also included financial statements and exhibits.
Why It Matters
This filing provides crucial updates on BioSig Technologies' financial activities and strategic agreements, which could impact its stock performance and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and regulatory risks.
Key Players & Entities
- BioSig Technologies, Inc. (company) — Registrant
- May 29, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-38659 (identifier) — Commission File Number
- 26-4333375 (identifier) — IRS Employer Identification No.
- 55 Greens Farms Road (address) — Principal executive offices street
- Westport (location) — Principal executive offices city
- CT (location) — Principal executive offices state
- 06880 (postal_code) — Principal executive offices zip code
- (203) 409-5444 (phone_number) — Registrant's telephone number
FAQ
What specific material definitive agreement did BioSig Technologies enter into?
The filing does not specify the details of the material definitive agreement, only that one was entered into on or before May 29, 2024.
What type of equity securities were sold unregistered?
The filing mentions unregistered sales of equity securities but does not provide specific details about the type of securities sold.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on May 29, 2024.
Where is BioSig Technologies, Inc. headquartered?
BioSig Technologies, Inc.'s principal executive offices are located at 55 Greens Farms Road, 1st Floor, Westport, Connecticut 06880.
What is the IRS Employer Identification Number for BioSig Technologies, Inc.?
The IRS Employer Identification Number for BioSig Technologies, Inc. is 26-4333375.
Filing Stats: 1,953 words · 8 min read · ~7 pages · Grade level 13.7 · Accepted 2024-05-30 16:26:10
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share BSGM The NASDAQ Capital M
- $1.91 — pany (the "Common Stock") at a price of $1.91 per share and (ii) in a concurrent priv
- $1.78 — f Common Stock, at an exercise price of $1.78 per share of Common Stock. The securi
- $3.0 million — raising gross proceeds of approximately $3.0 million before deducting placement agent fees a
- $2.3875 — Offering and have an exercise price of $2.3875 per share of Common Stock. In addition,
- $35,000 — a non-accountable expense allowance of $35,000, clearing fees of $15,950 and accountab
- $15,950 — allowance of $35,000, clearing fees of $15,950 and accountable legal expenses and othe
- $50,000 — tion with the Offering in the amount of $50,000. The foregoing does not purport to be
Filing Documents
- form8-k.htm (8-K) — 56KB
- ex4-1.htm (EX-4.1) — 117KB
- ex4-2.htm (EX-4.2) — 116KB
- ex5-1.htm (EX-5.1) — 22KB
- ex10-1.htm (EX-10.1) — 265KB
- ex99-1.htm (EX-99.1) — 18KB
- ex99-2.htm (EX-99.1) — 18KB
- ex5-1_001.jpg (GRAPHIC) — 6KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001493152-24-021987.txt ( ) — 925KB
- bsgm-20240529.xsd (EX-101.SCH) — 3KB
- bsgm-20240529_lab.xml (EX-101.LAB) — 33KB
- bsgm-20240529_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOSIG TECHNOLOGIES, INC. Date: May 30, 2024 By: /s/ Anthony Amato Name: Anthony Amato Title: Chief Executive Officer